Median age, years, interquartile range |
10.5 |
(6, 14.3) |
(6,
14.3) |
(6, 14.3) |
0.74 |
Male |
50 |
68% |
68% |
68% |
0.79 |
Primary disorder malignancy |
24 |
32% |
32% |
32% |
1.00 |
Chemotherapy prior to referral for HSCT |
37 |
50% |
50% |
50% |
0.44 |
Sibling Donor |
29 |
39% |
39% |
39% |
0.12 |
Match 10/10 |
57 |
77% |
77% |
77% |
0.15 |
Transplant Source |
|
|
|
|
0.14 |
Peripheral blood
|
9
|
12%
|
12%
|
12%
|
|
Bone marrow
|
63
|
85%
|
85%
|
85%
|
|
Cord blood
|
2
|
3%
|
3%
|
3%
|
|
Myeloablative Allogeneic HSCT |
45 |
61% |
61% |
61% |
0.12 |
Total Body Irradiation |
12 |
16% |
16% |
16% |
0.41 |
Ex-vivo T cell depletion |
7 |
9% |
9% |
9% |
0.10 |
Outcomes† |
|
|
|
|
|
Stage 2+ Creatinine AKI in 1st year
|
44
|
70%
|
70%
|
70%
|
0.80
|
Dialysis ever
|
5
|
8%
|
8%
|
8%
|
0.63
|
Event free survival
|
55
|
87%
|
87%
|
87%
|
1.00
|
Abnormal creatinine eGFR >2 years post-SCT
|
12 of 39
|
31%
|
31%
|
31%
|
0.73
|
†Outcomes assessed in 63 patients. |
|
|
|
|
|